Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)

Trial Profile

Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Aug 2018

At a glance

  • Drugs Ublituximab (Primary) ; Teriflunomide
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ULTIMATE II
  • Sponsors TG Therapeutics Inc
  • Most Recent Events

    • 07 Aug 2018 According to a TG Therapeutics media release, though targeted enrollment has been achieved, in order to provide an opportunity for patients already identified to participate, enrollment is expected to continue until mid-September.
    • 07 Aug 2018 Status changed from recruiting to active, no longer recruiting, as reported in aTG Therapeutics media release
    • 02 Feb 2018 According to a TG Therapeutics media release, trial is currently enrolling and complete enrollment is expected in the first quarter of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top